Auxano Advisors LLC Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Auxano Advisors LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 521 shares of the medical research company’s stock after purchasing an additional 21 shares during the period. Auxano Advisors LLC’s holdings in Thermo Fisher Scientific were worth $288,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Signature Resources Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. LifeSteps Financial Inc. bought a new stake in Thermo Fisher Scientific during the first quarter worth approximately $31,000. New Millennium Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $29,000. Northwest Financial Advisors bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Finally, Stephens Consulting LLC raised its holdings in Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock valued at $30,000 after buying an additional 29 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $3.39 during trading on Friday, reaching $615.07. The stock had a trading volume of 1,058,979 shares, compared to its average volume of 1,105,470. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $622.30. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The stock has a market cap of $234.96 billion, a PE ratio of 39.45, a PEG ratio of 2.86 and a beta of 0.77. The business has a fifty day moving average price of $578.71 and a 200-day moving average price of $576.03.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company earned $5.15 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares of the company’s stock, valued at approximately $8,397,760.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $613.02, for a total value of $2,221,584.48. Following the transaction, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,084 shares of company stock worth $19,767,092. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. TD Cowen increased their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Jefferies Financial Group restated a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Finally, Barclays lowered their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $630.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.